Search for: "CIPLA"
Results 141 - 160
of 202
Sorted by Relevance
|
Sort by Date
29 Jan 2013, 10:44 am
Soon after, Prashant carried another brilliant post revealing the political economy and interplay behind the generic lobbying efforts that might have culminated into such an action by the Indian government and role played by Yusuf Hamied, the head of Cipla. [read post]
4 Dec 2013, 7:06 am
Cipla Ltd., 681 F.3d 1283, 1299 (Fed. [read post]
7 Sep 2010, 6:10 pm
biuras, Amgen Europe BV (The SPC Blog) Aricept (Donepezil) – US: District Court denies Apotex declaratory judgment motion on generic Aricept; does not accept ‘prompt launch’ and ‘indefinite delay’ jurisdiction theories (FDA Law Blog) Chantix (Varenicline) – US: Pfizer files patent infringement complaint against Mylan following Para IV challenge (Patent Docs) (AboutLawsuits.com) Copaxone (Glatiramer) – US: Court denies Sandoz/Momenta’s summary judgment… [read post]
22 Mar 2011, 4:21 pm
: Board of Trustees of Leland Stanford Junior University v Roche Molecular Systems Inc (IPKat) US: That was unexpectedly… well… expected: BPAI affirms Examiner’s obviousness rejection in Ex Parte Akio Ochiai concerning a health food product containing curcumin, scymnol and isoflavones (BT-IP Notes) US: VirginiaTech VERSUS series – Drug evaluation DVDs available (FDA Law Blog) Products Diovan HCT (Valsartan, Hydrochlorothiazide) – Germany: Düsseldorf… [read post]
27 Jun 2011, 11:47 am
pricing debate (Roche vs Cipla), Compulsory Licensing: Export of patented drugs (Pfizer/ Roche vs Natco), Linkages in Indian Patent System (Custom enforcement, Biopharmaceuticals, Marketing –Approval and EMR, Efficacy testing, Competition, Working). [read post]
25 Aug 2010, 12:37 am
(Patent Docs) (The IP Factor) Dexpramipexole – US: Knopp Neurosciences deal shows how IP strategy can build value for licensing (IP Spotlight) Dulera (Formoterol Fumarate and Mometasone Furoate) – India: Novartis loses Dulera patent in India (Patent Circle) Evoxac (Cevimeline) – US: Daiichi, Apotex reach settlement in Evoxac patent suit (Patent Docs) HPV detection kit – US: Arbitration award to Roche and Gen-Probe approved in HPV license suit with Qiagen (Patent Docs) I-pill… [read post]
19 Dec 2008, 1:00 pm
$16.8 million for Alphapharm and Mylan: Takeda v Mylan (Patent Baristas) (Patent Docs) Boniva (Ibandronic acid) – US: Apotex challenges validity of Hoffmann-La Roche’s Boniva patent (Law360) Boniva (Ibandronic acid) – US: Orchid Chemicals & Pharmaceuticals and Orgenus Pharma seek declaratory judgment of invalidity and noninfringement in patent infringement suit brought by Hoffmann-La Roche over Boniva (Law360) Cardizem (Diltiazem) – Antitrust,… [read post]
8 May 2009, 8:00 am
(Property intangible) US: Supreme Court rules 9-0 that CAFC has jurisdiction to review case remanded by district court to state court: Carlsbad Technology Inc v HIF Bio, Inc et al (Managing Intellectual Property) (Patently-O) US: Anticipation by a laundry list of prophetic DNA sequences: In re Gleave (Holman's Biotech IP Blog) US: Reverse payment settlements and biotechnology (Holman's Biotech IP Blog) US: Biogen seeks review and correction of patent term adjustment calculation in respect… [read post]
4 Mar 2009, 11:00 pm
(Spicy IP) Kenya enacts Biosafety Act 2/2009 regulating activities in GMOs, establishing National Biosafety Authority (Afro-IP) US: BIO meets the press: economic health of the biotech industry; follow-on biologics; patent reform (Patent Docs) (Patent Docs) (Intellectual Property Watch) US: Obama touts generic biologics to lower drug costs (Law360) US: Genentech announces victory in Cabilly re-examination (Patent Docs) US: Federal judge rejects Scruggs family’s bid to reconsider summary… [read post]
12 Dec 2008, 7:00 am
EU: European Commission preliminary report on its inquiry into competition in the pharmaceutical sector (Spicy IP) (Intellectual Property Watch) (Patent Baristas) EU: Enlarged Board of the EPO denies WARF’s patent application directed to human embryonic stem cells (Patent Docs) US: Patent Office assault on pharma industry (PLI) US: Proponent of gene patent ban Rep Xavier Becerra to leave Congress (Patent Docs) US: Merck & Co starts generic arm BioVentures to copy biologic medicine… [read post]
27 Sep 2008, 12:08 am
(Biotech Blog) United States: Patent for generating oxygen in a process that mimics photosynthesis (Competitive info) Products Adderall (Dextroamphetamine/Racemic DL-ampthetamine) - US: Judge denies Sandoz’ bid for summary judgment of non infringement in patent dispute with Shir eover Adderall (Law360) Carbatrol (Carbamazepine) - US: Judge refuses to grant summary judgment to Corepharma in patent dispute with Shire Laboratories over generic Carbatrol (Law360) Clarinex… [read post]
5 Aug 2012, 7:34 am
It should be remembered that companies like Cipla derive almost 40% to 50% of their annual revenues from American and European markets. [read post]
25 Nov 2009, 12:00 pm
You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: http://duncanbucknell.com/subscribe/ Highlights this week included: Ecuador to define its compulsory licence legislation (IP Watch) (Patently-O) Tavanic (Levofloxacin) – UK: Supreme Court refuses permission to appeal in Generics (UK) Ltd v Daiichi Pharmaceuticals (The SPC Blog) (JIPLP) General Nil: The value of patents in a major crisis such as an influenza pandemic – Paper by… [read post]
15 Jul 2011, 7:40 am
It is also manufactured and marketed by Cipla under trade name Tiova. [read post]
1 Jul 2009, 7:14 am
OHIM decision in Laboratorios Andrómaco, S.A. v OTC Pharma International B V (Class 46) India: Valgancyclovir hearings and the need for more transparency: Roche v Cipla (Spicy IP) Japan approves first follow-on biologic (Patent Docs) UK: Journal of Intellectual Property Law & Practice note on ‘Paediatric extensions: the requirement of a compliance statement’ on UK IPO decision in Merck and Co, Inc (The SPC Blog) US: Sen Nelson introduces s 1315 bill to… [read post]
3 Apr 2017, 2:22 pm
Cipla Ltd., 681 F.3d 1283, 1304–05 (Fed. [read post]
25 Mar 2020, 3:00 pm
Cipla Ltd., 681 F.3d 1283, 1299 (Fed. [read post]
23 Feb 2013, 10:22 pm
He examines the decision of the Controller in the Sugen v Cipla’s post-grant opposition and points out several junctures at which the Controller has failed to provide necessary authority and has almost as if sworn not to use precedents set by the IPAB to back its conclusions. [read post]
Guest Post: Eye witness account of India's first compulsory license appeal before the IPAB [Part II]
8 Mar 2013, 2:47 am
The Board then deliberated on the suppression of CIPLA’s presence and the filing of counterclaims by the respondent and the false s [read post]
2 Nov 2012, 2:38 am
One wonders why pharmaceutical patentees refuse to drop prices, despite being at the receiving end of high court orders (Roche vs Cipla, where Justice Bhat refused to grant an injunction on the grounds of the excessive price differential between the patented drug and the allegedly infringing generic) and compulsory licensing decisions. [read post]
